These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 3558048

  • 1. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain.
    Chaplin DJ, Acker B.
    Int J Radiat Oncol Biol Phys; 1987 Apr; 13(4):579-85. PubMed ID: 3558048
    [Abstract] [Full Text] [Related]

  • 2. Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT).
    Chaplin DJ.
    Br J Cancer; 1986 Nov; 54(5):727-31. PubMed ID: 3801269
    [Abstract] [Full Text] [Related]

  • 3. Postirradiation modification of tumor blood flow: a method to increase the effectiveness of chemical radiosensitizers.
    Chaplin DJ.
    Radiat Res; 1988 Aug; 115(2):292-302. PubMed ID: 3406369
    [Abstract] [Full Text] [Related]

  • 4. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo.
    Stratford IJ, Adams GE, Godden J, Howells N.
    Int J Radiat Biol; 1989 Mar; 55(3):411-22. PubMed ID: 2564037
    [Abstract] [Full Text] [Related]

  • 5. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
    Cole S, Stratford IJ, Bowler J, Nolan J, Wright EG, Lorimore SA, Adams GE.
    Int J Radiat Oncol Biol Phys; 1991 Jul; 21(2):387-95. PubMed ID: 2061115
    [Abstract] [Full Text] [Related]

  • 6. The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor.
    Chaplin DJ, Durand RE, Stratford IJ, Jenkins TC.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1091-5. PubMed ID: 3755714
    [Abstract] [Full Text] [Related]

  • 7. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
    Cole S, Stratford IJ, Adams GE, Fielden EM, Jenkins TC.
    Radiat Res; 1990 Oct; 124(1 Suppl):S38-43. PubMed ID: 2236508
    [Abstract] [Full Text] [Related]

  • 8. Manipulation of oxygenation in a human tumour xenograft with BW12C or hydralazine: effects on responses to radiation and to the bioreductive cytotoxicity of misonidazole or RSU-1069.
    Cole S, Robbins L.
    Radiother Oncol; 1989 Nov; 16(3):235-43. PubMed ID: 2587812
    [Abstract] [Full Text] [Related]

  • 9. RSU 1069, a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitizer in vitro and in vivo.
    Adams GE, Ahmed I, Sheldon PW, Stratford IJ.
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1653-6. PubMed ID: 6548211
    [Abstract] [Full Text] [Related]

  • 10. Cytotoxicity of RSU 1069 in spheroids and murine tumors.
    Olive PL, Durand RE, Chaplin DJ.
    Int J Radiat Oncol Biol Phys; 1987 Sep; 13(9):1361-6. PubMed ID: 3624045
    [Abstract] [Full Text] [Related]

  • 11. The chemosensitizing and cytotoxic effects of RSU 1164 and RSU 1165 in a murine tumor model.
    Siemann DW.
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1115-8. PubMed ID: 2703392
    [Abstract] [Full Text] [Related]

  • 12. Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice.
    Kanclerz A, Chapman JD.
    Int J Radiat Oncol Biol Phys; 1988 Feb; 14(2):309-16. PubMed ID: 2828290
    [Abstract] [Full Text] [Related]

  • 13. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
    Cole S, Stratford IJ, Fielden EM, Adams GE, Leopold W, Elliott W, Suto M, Sebolt-Leopold J.
    Int J Radiat Oncol Biol Phys; 1992 Feb; 22(3):545-8. PubMed ID: 1735694
    [Abstract] [Full Text] [Related]

  • 14. Synergistic enhancement of the efficacy of the bioreductively activated alkylating agent RSU-1164 in the treatment of prostatic cancer by photodynamic therapy.
    Henry JM, Isaacs JT.
    J Urol; 1989 Jul; 142(1):165-70. PubMed ID: 2733098
    [Abstract] [Full Text] [Related]

  • 15. Cytocidal effects of misonidazole, Ro 03-8799, and RSU-1164 on euoxic and hypoxic BP-8 murine sarcoma cells at normal and elevated temperatures.
    Hofer KG, Lakkis M, Hofer MG.
    Cancer; 1989 Apr 15; 63(8):1501-8. PubMed ID: 2924258
    [Abstract] [Full Text] [Related]

  • 16. Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069.
    Hill RP, Gulyas S, Whitmore GF.
    Br J Cancer; 1986 Jun 15; 53(6):743-51. PubMed ID: 3755053
    [Abstract] [Full Text] [Related]

  • 17. The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action.
    Stratford IJ, Walling JM, Silver AR.
    Br J Cancer; 1986 Mar 15; 53(3):339-44. PubMed ID: 3754453
    [Abstract] [Full Text] [Related]

  • 18. Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.
    Adams GE, Ahmed I, Sheldon PW, Stratford IJ.
    Br J Cancer; 1984 May 15; 49(5):571-7. PubMed ID: 6547051
    [Abstract] [Full Text] [Related]

  • 19. Hydralazine-induced tumor hypoxia: a potential target for cancer chemotherapy.
    Chaplin DJ.
    J Natl Cancer Inst; 1989 Apr 19; 81(8):618-22. PubMed ID: 2704051
    [Abstract] [Full Text] [Related]

  • 20. Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU-1069.
    Cole S, Stratford IJ, Adams GE.
    Int J Radiat Biol; 1989 Nov 19; 56(5):587-91. PubMed ID: 2573651
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.